Insurance Authorization Barriers in Patients Undergoing Cytoreductive Surgery and HIPEC.

Background: Indications for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) exist across multiple histologies, but little data exist on the impact of insurance authorization on access to these therapies. Given the evolving role of CRS/HIPEC, we sought to characterize insurance approval and delays in patients undergoing these therapies.

Patients And Methods: A retrospective review was performed at a high-volume tertiary center of patients who received CRS/HIPEC from 2017 to 2021.